311
Views
6
CrossRef citations to date
0
Altmetric
Review

Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia

&
Pages 59-67 | Received 17 Oct 2019, Accepted 29 Nov 2019, Published online: 13 Dec 2019

References

  • Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012;5(Suppl 1):i3- i14.
  • Ismail AA. Magnesium: A mineral essential for health yet generally underestimated or even ignored. J Nutr Food Sci. 2016;6(4):2.
  • Grober U. Magnesium and drugs. Int J Mol Sci. 2019;20:2094.
  • de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95:1–46.
  • Kostov K, Halacheva L. Role of magnesium deficiency in promoting atherosclerosis, endothelial dysfunction, and arterial stiffening as risks factors for hypertension. Int J Med Sci. 2018;19(6):1724.
  • Kolte D, Vijayaraghavan K, Khera S, et al. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014;22(4):182–192.
  • Moshfegh A, Goldman J, Ahuja J, et al. What we eat in America, NHANES 2005–2006. Usual nutrient intakes from food and water compared to 1997 reference intakes for vitamin D, calcium, phosphorus, and magnesium. US Department of Agriculture, Agricultural Research Service. 2009. cited 2019 Apr 6 http://www.ars.usda.gov/SP2UserFiles/Place/12355000/pdf/0506/usual_nutrient_intake_vitD_ca_phos_mg_2005.pdf
  • Al-Ghamdi MB, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis. 1994;24(5):737–752.
  • Whang R, Chrysant SG, Dillard B, et al. Hypomagnesemia in 1000 treated ambulatory hypertensive patients. J Am Coll Nutr. 1982;1(4):317–322.
  • Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. Am Heart J. 1979;97:12–18.
  • Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(10):1834–1836.
  • Ray WA, Chung CP, Murray KT, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105–1112.
  • Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advise from the American gastroenterological association. Gastroenterology. 2017;152(4):706–715.
  • Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123–1134.
  • Ali Khan M, Howden C. The role of proton pump inhibitors in the management of upper gastrointestinal disorders. Gastroenterol Hep. 2018;14(3):169–173.
  • Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56(1):112 116.
  • Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton pump inhibitors. Expert Opin Drug Saf. 2013;12(5):709–716.
  • Kim S, Lee H, Park CH, et al. Clinical predictors associated with proton pump inhibitor-induced hypomagnesemia. Am J Ther. 2015;22(1):14–21.
  • Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–1241.
  • Byik M, Solak Y, Ucar R, et al. Hypomagnesemia among outpatients long-term proton pump inhibitor users. Am J Ther. 2017;24(1):e52- e55.
  • Burdsall P, Flores HC, Krueger J, et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. J Am Med Dir Assoc. 2013;14(6):429–432.
  • Patterson Burdsall D, Flores HC, Krueger J, et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. J Am Dir Assoc. 2013;14(6):429–432.
  • Famularo G, Minisola G, Bravi MC, et al. Tetany, hypomagnesemia, and proton pump inhibitors. Am J Med. 2012;125(5):e7–8.
  • Deroux A, Khouri C, Chabre L, et al. Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia. Clin Res Hepatol Gastroenterol. 2014;38(5):e103–105.
  • Lazzerini PE, Bertolozzi I, Finizola F, et al. Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes. Front Pharmacol. 2018;9(4):363.
  • Dyckner T, Wester PO. Intracellular magnesium loss after diuretic administration. Drugs. 1984;28(Suppl. 1):161–166.
  • Agus ZS. Mechanisms and causes of hypomagnesemia. Curr Opin Nephrol Hypertens. 2016;25(4):301–307.
  • William JH, Danziger J. Proton-pump inhibitor-induced hypomagnesemia: current research and proposed mechanisms. World J Nephrol. 2016;5:152–157.
  • Schingmann KP, Waldegger S, Konrad M, et al. TRPM6 and TRPM7-gatekeepers of magnesium metabolism. Biochem Biophys Acta. 2007;1772(8):821–823.
  • Mackkay JD, Bladon PT. Hypomagnesemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010;103(6):387–395.
  • Michalelk W, Sempler JR, Kuo B. Impact of acid suppression on upper gastrointestinal pH and motility. Dig Dis Sci. 2011;56(6):1735–1742.
  • Asajima H, Saito N, Ohmura Y. Lansoprazole precipitated QT prolongation and torsades de points associated with disopyramide. Eur J Clin Pharmacol. 2012;68(3):331–333.
  • El-Charabaty E, Saifan C, Abdallah M, et al. Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013;6(6):515–518.
  • Bibawy JN, Parikh V, Wahba J, et al. Pantoprazole (proton pump inhibitor) contributing to torsades de pointes storm. Circ Arrhyth Electrophysiol. 2013;6(2):e17- e20.
  • Hansen BA, Bruserud O. Hypomagnesemia as a potentially life-threatening adverse effect of omeprazole. Oxf Med Case Rep. 2016;2016(7):147–149.
  • Dos Santos LM, Guerra RA, Lazzaretti-Castro M, et al. An approach to the diagnosis and management of a case presenting with recurrent hypomagnesemia secondary to chronic use of proton pump inhibitor. Magnes Res. 2015;28(4):136–145.
  • Verbrugge FH, Steels P, Grieten L, et al. Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol. 2015;65:480–492.
  • Reyes AJ, Leary WP. Diuretic therapy, magnesium deficiency and lipid metabolism. S Afr Med J. 1983;64:355–356.
  • Weidmann P, de Courten M, Ferrari P. Effects of diuretics on the plasma lipid profiles. Eur Heart J. 1992;13(Suppl. G):61–67.
  • Leary WP, Reyes AJ. Diuretic-induced magnesium losses. Drugs. 1984;28(Suppl 1):182–187.
  • Durlach J, Durlach V, Rayssiguier Y, et al. Magnesium and blood pressure. II. Clinical studies. Magnes Res. 1992;5:147–153.
  • Resnick LM, Bardicef O, Altura BT, et al. Serum ionized magnesium: relation to blood pressure and racial factors. Am J Hypertens. 1997;10(12 Pt 1):1420–1424.
  • Fox CH, Ramsoomair D, Mahoney MC, et al. An investigation of hypomagnesemia among ambulatory urban African Americans. J Fam Pract. 1999;48:636–639.
  • Rodriguez-Ramirez M, Simental-Mendia LE, Gonzales-Ortiz M, et al. Prevalence of prehypertension in Mexico and its association with hypomagnesemia. Am J Hypertens. 2015;28:1024–1030.
  • Chrysant SG, Ganousis L, Chrysant C. Hemodynamic and metabolic effects of hypomagnesemia in spontaneously hypertensive rats. Cardiology. 1988;75:81–89.
  • Sontia B, Touyz RM. Magnesium transport in hypertension. Pathophysiology. 2007;14:205–211.
  • Heggtveit HA, Herman L, Mishra RK. Cardiac necrosis and calcification in experimental magnesium deficiency. Light and electron microscopic study. Am J Path. 1964;45:757–782.
  • Kisters K, Tepel M, Spieker C, et al. Decreased membrane Mg2+ concentrations in a group of hypertensives: membrane model for pathogenesis of primary hypertension. Am J Hypertens. 1998;11:1390–1393.
  • Kosch M, Hausberg M, Westermann G, et al. Alterations in calcium and magnesium content of red cell membranes in patients with primary hypertension. Am J Hypertens. 2001;14:254–258.
  • Kisters K, Wessels F, Tokmak F, et al. Early-onset increased calcium and decreased magnesium concentrations and an increased calcium/magnesium ratio in SHR versus WKY. Magnes Res. 2004;17:264–269.
  • Dyckner T, Wester PO. Ventricular extrasystoles and intracellular electrolytes before and after potassium and magnesium infusions in patients with diuretic treatment. Am Heart J. 1979;97:12–18.
  • Dyckner T, Wester PO. Magnesium deficiency contributing to ventricular tachycardia. Two case reports. Acta Med Scand. 1982;212:89–91.
  • Sheehan J, White A. Diuretic-associated hypomagnesemia. BMJ. 1982;285:1157.
  • Hollifield JW. Thiazide treatment of hypertension. Effects of thiazide diuretics on serum potassium, magnesium, and ventricular ectopy. Am J Med. 1986;80(4A):8–12.
  • Hollifield JW. Thiazide treatment of systemic hypertension: effects on serum magnesium and ventricular ectopic activity. Am J Cardiol. 1989;63(14):22G- 25G.
  • Hinson AM, Wilkerson BM, Rothman-Fitts I, et al. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J Am Geriatr Soc. 2015;63:2070–2073.
  • Kelepouris E, Kassama R, Agus ZS. Effects of intracellular magnesium on calcium, potassium and chloride channels. Mine Electrolyte Metab. 1993;19:277–281.
  • El-Serif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011;18:233–245.
  • Sanguinetti MC, Tristani-Farouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(3):463–469.
  • Recanatini M, Poluzzi E, Masetti M, et al. QT prolongation through hERGK+ channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev. 2005;25:133–166.
  • Zhao M, Feng R, Shao D, et al. Mg2+ - dependent facilitation and inactivation of L-type Ca2+ channels in guinea pig ventricular myocytes. J Pharmacol Sci. 2015;129:143–149.
  • Viskin S. Long QT syndromes and torsades de points. Lancet. 1999;354:1625–1633.
  • Edwards JN, Blatter LA. Cardiac alternans and intracellular calcium cycling. Clin Exp Pharmacol Physiol. 2014;41(7):524–532.
  • Tse G, Hons BA, Wong ST, et al. Cardiac dynamics: alternans and arrhythmogenesis. J Arrhyth. 2016;32:411–417.
  • Khan AM, Lubitz SA, Sullivan LM, et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2013;127(1):33–38.
  • Gu WJ, Wu ZJ, Wang PF, et al. Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials. Trials. 2012;13(4):41.
  • Onalan O, Crystal E, Daoulah A, et al. Meta-analysis of magnesium therapy for acute management of rapid atrial fibrillation. Am J Cardil. 2007;99(12):1726–1732.
  • Ho KM. Intravenous magnesium for cardiac arrhythmias: a jack of all trades. Magnes Res. 2008;21(1):65–68.
  • Liamis G, Rodenburg EM, Hofman A, et al. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med. 2013;126:256–263.
  • Sharara AI, Chalhoub JM, Hammound N, et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin Gastroenterol Hepatol. 2016;14(2):317–321.
  • Hess MW, de Baaij JH, Broekman MM, et al. Common single nucleotide polymorphism in transient receptor potential melastatin type 6 increase the risk of proton pump inhibitor-induced hypomagnesemia: a case-control study. Pharmacogenet Genomics. 2017;27(3):83–88.
  • Napolitano C, Priori SG, Schwartz PTDP. Mechanisms and treatment. Drugs. 1994;47(1):51–65.
  • FDA drug Safety communication: low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). cited Oct 8, 2019 https://www.fda.gov/drugs/drugsafety/ucm245011.htm
  • Reed LG, Mok JY. Proton pump inhibitor-associated hypomagnesemia: a retrospective case-control study. Fed Pract. 2016;33(!@):18–21.
  • Tamura T, Sakaeda T, Kadoyama K, et al. Omeprazole-and esoprazole-associated hypomagnesemia. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2012;9(6):322–326.
  • Alhosaini M, Leehey DJ, Kavitha V Proton pump inhibitors are associated with severe hypomagnesemia in renal transplant patients. Neprology Times. Abstract presented at Kidney Week 2014, November 13, Philadelphia PA.
  • Whang R, Whang DD, Ryan MP. Refractory potassium repletion. A consequence of magnesium deficiency. Arch Intern Med. 1992;152:40–45.
  • Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28:615–620.
  • Kass L, Sullivan KR. Low dietary magnesium intake and hypertension. World J Cardiovasc Dis. 2016;6(12):447–457.
  • Gu X, Jin F, Mao Y, et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PloS One. 2013;8(3):e57720.
  • Dyckner T, Wester PO. Potassium/magnesium depletion in patients with cardiovascular disease. Am J Med. 1987;82(3A):11–17.
  • Thongon N, Penguy J, Kulwong S, et al. Omeprazole suppressed plasma magnesium level and duodenal magnesium absorption in male Sprague-Dawley rats. Eur J Physiol. 2016;468:1809–1821.
  • Leary WP. Content of magnesium in drinking water and death from ischemic heart disease in White South Africans. Magnesium. 1986;5:150–153.
  • Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother. 1994;28:220–226.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.